

1 **Tropism, susceptibility, infectivity, and cytokine releases of differentiated human tonsillar**  
2 **epithelial cells by different Influenza viruses.**

3

4 Faten Okda <sup>a</sup>, Ahmed Sakr <sup>b</sup>, Robert Webster <sup>a</sup> and Richard Webby <sup>a#</sup>.

5

6 <sup>a</sup> Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis,

7 Tennessee, USA

8 <sup>b</sup> Department of business Administration, Dakota state University, Madison, USA

9

10 Running Head: Role of Tonsils in Influenza viruses Infections

11

12 #Address correspondence to Richard Webby, [richard.webby@stjude.org](mailto:richard.webby@stjude.org).

13

14 Abstract word count:

15 230

16 Main text word count: 9905

17

18 **ABSTRACT**

19 Human tonsil epithelium cells (HTEC) are a heterogeneous group of actively differentiating cells  
20 comprising stratified squamous epithelial and reticulated crypt cells with abundant keratin  
21 expression. We hypothesized that the tonsils are a primary site for influenza infection and  
22 sustained viral replication. Primary HTEC were grown using an air-liquid culture and infected  
23 apically with different influenza viruses (IVs) to measure viral growth kinetics. These cultures  
24 were highly differentiated, with subpopulations of heterogenous surface stratified squamous cells  
25 rich with both cilia and microvilli; these cells contained more  $\alpha$ 2,6-linked sialic acids, those  
26 preferentially bound by human IVs, than  $\alpha$ 2,3-linked avian like sialic acids. The stratified  
27 squamous cells were interrupted by patches of reticular epithelial cells rich in  $\alpha$ 2,3-linked sialic  
28 acids. The HTEC were permissive for influenza A and B virus replication. Following infection, a  
29 subset of cells, mostly ciliated cells, underwent apoptosis while others remained intact despite  
30 being positive for IV nucleoprotein. H3N2 virus antigen colocalized with non-ciliated cells while  
31 H1N1 virus antigen was mostly associated with ciliated cells. Exposure of HTECs to IVs triggers  
32 an early proinflammatory response that fluctuates between viruses. The H3N2 IV induces an  
33 early response that persists, whereas pH1N1 induces a primarily late response in HTECs. Our  
34 results implicated HTEC as a site for IV replication. The HTEC differentiated system provides a  
35 valuable in vitro model for studying cellular tropism, infectivity, cytokine responses and the  
36 pathogenesis of IVs.

37

38 **IMPORTANCE**

39 To develop an effective intervention against influenza, it is important to identify host factors  
40 affecting transmission, pathogenesis, and immune response. Tonsils are lymphoepithelial organs

41 characterized by infiltration of B and T lymphocytes into the squamous epithelium of tonsillar  
42 crypts, beneath which germinal centers play key roles in antigen processing and immune  
43 response. The heterogenicity of HTECs as well as the sialic acid distributions supports the  
44 replication of IVs and may play a role in IV adaptation. Furthermore, Tonsillectomy is a surgical  
45 procedure in which tonsils are fully removed from the human throat and may contribute to the  
46 diverse outcomes among infected individuals.

47

48 **KEYWORDS**

49 Tonsils, crypts, squamous epithelial cells, keratin, reticular epithelial cells, adaptation,  
50 pathogenesis, cytokines, chemokines, influenza virus, H1N1, H3N2, WSN

## 51 INTRODUCTION

52 Influenza viruses (IVs) are an important health threat due to annual disease outbreaks and  
53 pandemic risks (1–3). To date, no effective universal vaccine against IVs has been developed  
54 partly because of a limited understanding of IV pathogenesis (4). Identifying the host and  
55 virologic factors contributing to IV disease severity are critical to influenza control (1, 4). The  
56 tonsils are lymphoid organs located on either side of the back of the human throat (5) that consist  
57 of heterogeneous lymphoepithelial cells. The tonsils are comprised of two different types of  
58 actively differentiating epithelia: the lining stratified squamous epithelium and the reticulated  
59 crypt, or lymphoepithelium (6).

60 Each human tonsil contains a network of pits known as crypts, which are branched  
61 invaginations lined by stratified squamous epithelia that extend throughout the full thickness of  
62 the tonsil. The tonsillar crypts represent a specialized compartment that is critical for the  
63 immunologic functions of the tonsils. The tonsillar crypts play a role in facilitating contact  
64 between environmental factors and lymphoid tissues, in which many lymphoid cells pass  
65 through. These lymphoid cells may escape into the epithelium and mix with the saliva to form  
66 salivary corpuscles (7).

67 The surface stratified squamous epithelium differs from a simple ciliated epithelium because  
68 it acts as an extracellular matrix and surface, controls tissue integrity, and mediates intracellular  
69 signaling pathways and immunologic functions (6, 8). The tonsil epithelium monitors and  
70 protects the body against respiratory and gastrointestinal infections (9). Typically, lymphocytes  
71 infiltrate into the squamous epithelium of the tonsillar crypts and mucosal surface. The tonsils  
72 have several local and systemic immunologic functions that involve innate, cellular, and humoral  
73 immunity (6). The tonsils confer immunity against entering pathogens and enable efficient and

74 rapid systemic immune responses by antigen sampling, intracellular signaling pathways, and  
75 movement of lymphocytes, cytokines, and chemotactic molecules from the tonsils to other  
76 lymphoid organs. The tonsils contain a germinal center, in which B memory cells and secretory  
77 antibodies (IgA) are produced. Activated cells in mucosa-associated lymphoid tissues primarily  
78 secrete local IgA-type antibodies (6, 9). However, the role of the tonsil epithelia in IV  
79 pathogenesis remains uncertain.

80 Children are susceptible to tonsillitis because their tonsils are more active and have been  
81 exposed to fewer pathogens than those of adults. Tonsillectomy procedures fully remove the  
82 tonsils from the human throat (10). Tonsillectomy data collected over the last 60 years reveal  
83 decreased trends of tonsillectomy procedures performed in the United States (11, 12); however,  
84 the percentage of human subpopulations without tonsils is high at different ages (12, 13). Tonsil  
85 removal is considered a controversial environmental factor in inflammatory diseases, such as  
86 Crohn disease, because of the depletion of CD4<sup>+</sup>/CD25<sup>+</sup> T-regulatory cells (14). Tonsillectomy is  
87 also associated with an increased risk of Behcet disease (15), poliomyelitis (16–18), and  
88 respiratory, infectious, and allergic diseases (19). Of 1.2 million Danish children who received  
89 tonsillectomies, 43 207 had increased risk of developing respiratory, infectious, and allergic  
90 conditions. High mortality risk was reported in young adults who received tonsillectomies  
91 because of poor lung function (20). Moreover, an increased risk of autoimmune conditions such  
92 as thyroid disease, rheumatic diseases, and type 1 diabetes occurred in 179 875 Swedish patients  
93 who received tonsillectomies (21). Tonsillectomy is also associated with a higher risk of cancer  
94 (22–24) and premature acute myocardial infarctions (25). The prevalence of IV infections,  
95 disease severity, and immunity levels in patients without tonsils is poorly defined.

96 The tonsils are an initial site of replication of foot-and-mouth disease virus (FMDV) (26),  
97 polyomavirus (27), HIV (28), and Epstein–Barr virus (5, 8). Porcine tonsils are primary infection  
98 sites for FMDV after simulated natural virus exposure and facilitate replication in the clinical  
99 phase, yielding high amounts of viral shedding into the environment due to extensive  
100 amplification (26). HIV specifically targets the tonsils because of the interaction with HIV  
101 targets in this tissue (28).

102 We hypothesize that the tonsils are a primary site for IV infection and contribute to viral  
103 pathogenesis. IVs cause febrile respiratory infections ranging from self-limited to severe  
104 symptoms in children and adults. Children aged 5–14 years with pandemic H1N1 (pH1N1)  
105 infections experienced a high rate of hospitalizations, including acute respiratory distress  
106 syndrome (29, 30). The virulence of pH1N1 in children is linked to the downregulation of type 1  
107 interferon expression, apoptosis, and hyperinduction of proinflammatory cytokines (31). In  
108 contrast, the 1918 H1N1 pandemic IV caused severe infections in healthy individuals aged 15 to  
109 34 years (32, 33) because of exaggerated proinflammatory immune responses (34). Upregulation  
110 of inflammatory cytokines and chemokines are associated with the severity of influenza (35),  
111 which may benefit from immunomodulatory therapy. Identifying the pathways involved is  
112 critical. Here, we investigated the pathogenesis of IVs in a human tonsillar epithelial cell  
113 (HTEC) culture model to glean insight into the contribution of the tonsils to the diverse  
114 outcomes and immune responses of IV infections in humans.

115

116

117

118

119

120

## 121 **RESULTS**

122 **Tonsillectomy.** We analyzed the number of tonsillectomies performed within the last 40 years in  
123 the United States. A high percentage of tonsillectomies have been performed, leading to 25% to  
124 60% of the US population without tonsils (Fig. 1).

125

126 **Human tonsillar epithelial cell culture model.** To elucidate the contribution of the tonsils to IV  
127 pathogenesis and immune responses, we established a highly differentiated HTEC model. Phase-  
128 contrast microscopy images revealed that the HTECs were heterogeneous, with different cell  
129 sizes, types, and cytoplasm-to-nucleus ratios. Some HTECs acquired a very large cytoplasm-to-  
130 nucleus ratio, indicative of differentiated squamous epithelial cells, and subsets of differentiated  
131 morphologically large epithelial cells appeared in the cultures over time (Fig. 2A). Scanning  
132 electron microscopy (SEM) imaging revealed that the apical surface of the HTECs contained  
133 microvilli of approximately 5  $\mu\text{m}$ , and few ciliated epithelial cells were present (Fig. 2B).

134

135 **Morphological examination of well differentiated HTEC cultures.** To further characterize our  
136 HTEC model, we stained the cells with a panel of monoclonal antibodies against epithelial K5  
137 and K14 as markers of surface stratified epithelial cells (Fig. 3A) and K8/18 and K19 (Fig. 3B)  
138 as markers of the tonsillar crypts. We also stained the HTECs with antibodies against  $\beta$ -tubulin  
139 as a marker of cilia and villin as a marker of microvilli. We found that the differentiated HTECs  
140 consisted of a layered surface stratified epithelium with K5<sup>+</sup> and K14<sup>+</sup> cells (Fig. 3A). Although  
141 the K5<sup>+</sup> cells exhibited abundant cilia and microvilli, the K14<sup>+</sup> cells had more microvilli and less

142 cilia (Fig. 3A). The tonsillar crypt structures detected by K8/18 and K19 expression had an  
143 abundant distribution of cilia and microvilli but more microvilli and fewer cilia (Fig. 3B).  
144 Infiltration of the intercellular spaces by lymphocytes was also evident in the HTECs (Fig. 3).

145

146 **Sialic acid distribution in HTECs.** To determine the sialic acid (SA) distribution in the well-  
147 differentiated HTECs, we used the *Sambucus nigra* agglutinin (SNA) and *Maackia*  
148 *amurensis* agglutinin II (MAA II) lectins to visualize avian-  $\alpha 2,6$ - and human-virus  $\alpha 2,3$ -linked  
149 SA receptors, respectively. Both  $\alpha 2,3$  and  $\alpha 2,6$ -linked SA receptors (green) were present on both  
150 the surface stratified ( $K5^+$  and  $K14^+$ , red) and crypt epithelia ( $K8/18^+$  and  $K19^+$ , red) (Fig. 4).  
151 Few ciliated cells and surface stratified epithelial cells were rich in human-virus  $\alpha 2,6$ -linked SA  
152 receptor (Fig. 4A, C). However, the microvilli-containing epithelial cells and reticular crypt cells  
153 were rich in  $\alpha 2,3$ -linked SA (Fig. 4B, C).

154

155 **Susceptibility of HTECs to IV infection.** To investigate the susceptibility of the HTECs to IV  
156 infection, we used various IVs (Table 1) to infect the HTECs *in vitro*. If the tonsillar epithelia are  
157 important for IV pathogenesis, adaptation, and transmission, these cells will be susceptible to  
158 infection with swine, avian, and human IVs. Indeed, we found that the HTECs were permissive  
159 for the growth of various A and B IVs (Table 1).

160

161 **Viral replication kinetics.** To analyze the replication of WSN, pH1N1, and seasonal H3N2 IVs  
162 in HTECs, we infected them from the apical side of the air-liquid interface. We analyzed single-  
163 step (Fig. 5A) and multistep growth curves (Fig. 5B). With single-step replication, we found that  
164 the titers of released WSN were markedly higher than those of pH1N1 and H3N2 after 4 h of



165 infection (Fig. 5A). WSN titers began to decline at 12 h PI (post infection) at a point where  
166 H3N2 titers were highest. The H3N2 IV maintained high titers until 40 h post infection, whereas  
167 pH1N1 exhibited late replication kinetics, with high viral titers at 24 h PI (Fig. 5A). To  
168 understand the long-term influence of IV infection in HTECs, we analyzed multiple-step kinetics  
169 of the three IVs. The H3N2 and WSN IVs exhibited high viral titers from day 1 PI and were  
170 maintained until day 8 post infection. In contrast, pH1N1 grew slower, and release began at day  
171 3 PI (Fig. 5B).

172 **Colocalization of IVs subtypes with well-differentiated HTEC.** To understand the long-term  
173 effects of IV infection in human tonsil cells, we performed quantitative analyses of the levels of  
174 infected HTEC surface stratified epithelial and crypt cells, as well as those characterized by cilia  
175 and microvilli. We infected well-differentiated HTECs with pH1N1 or H3N2 from the apical  
176 surface at a multiplicity of infection (MOI) of 0.1 and stained the cells at days 2, 5, and 7 PI to  
177 detect viral nucleoprotein (red), K5 (green), K14 (green), K8/18 (green), K19 (green), and cilia  
178 (green). The H3N2 IV was highly associated with reticulated nonciliated cells during initial  
179 replication (Fig. 6A). At day 2 post infection, the surface stratified epithelial and crypt cells were  
180 mildly infected with H3N2. At day 5 post infection, both the surface stratified and crypt cells  
181 were infected. At day 7 post infection, the crypt cells were mildly infected. Loss of surface  
182 stratified epithelial cells occurred in all virus infected HTECs, as compared with that of mock  
183 cultures at day 7 post infection.

184 The pH1N1 IV primarily infected ciliated cells and replicated efficiently in the surface  
185 stratified epithelium, despite a low and delayed initial infection rate (Fig. 6B). At day 2 post  
186 infection, no viral nucleoprotein antigen was detected. However, at day 5 post infection, both the  
187 surface stratified and crypt epithelial cells were infected, with abundant IV present in the ciliated

188 cells. Of note, the number of ciliated cells was clearly increased at this time. At day 7 post  
189 infection, the surface stratified epithelial cells were lysed, and the crypt cells remained intact,  
190 with infection of some ciliated cells but less than at 5 days post infection. The microvilli were  
191 infected with all of the IVs but colocalized more with the H3N2 virus. A subset of infected cells  
192 with pH1N1, mostly ciliated, underwent apoptosis, whereas others (including non-ciliated cells)  
193 remained intact despite IV nucleoprotein positivity. At day 2 post infection, all of the cell types  
194 were infected with the WSN virus and the surface stratified epithelial cells were lysed. The WSN  
195 virus replicated efficiently in both the surface stratified epithelial and crypt cells.

196 These results demonstrate that the H3N2 virus preferentially infects microvilli-rich cells,  
197 replicates early in surface stratified epithelial cells, and later infects the crypt cells, which remain  
198 intact. The pH1N1 IV preferentially infected ciliated cells and some non-ciliated cells with  
199 delayed infection. This indicates that the heterogeneity of HTECs supports the replication of  
200 various IVs and may play a role in IV adaptation.

201

202 **Cytokine and chemokine responses in HTECs.** Excessive cytokine responses are associated  
203 with severe influenza symptoms. To understand the cytokine profile of IV-infected HTECs, we  
204 examined the induction of various inflammatory cytokines and chemokines in response to  
205 infection with the various IV subtypes. We measured a panel of 49 cytokines in the supernatants  
206 from infected HTECs. We found that HTECs produced different chemokines and cytokines in  
207 response to pH1N1 and H3N2. The H3N2 IV upregulated VEGF, RANTES, MCP-1, IP-10, IL-  
208 8, IL-6, IL-1 $\alpha$ , IL-1 $\beta$ , GRO, INF- $\alpha$ 2, fractalkine, GM-CSF, TGA, FGF-2, and EGF during the  
209 course of infection. PDGF-AB/BB, IL-1 $\beta$ , PDGF-AA, and TNF- $\alpha$  were secreted only at days 3  
210 to 5 post infection. In contrast, TNF- $\beta$ , IL-5, IL-4, IL-2, IL-9, IL-13, and IL-12 were

211 downregulated in H3N2-infected cells (Fig. 7A). Infection with pH1N1 resulted in the same  
212 pattern as that of H3N2, but PDGF-AA and TNF- $\beta$  were upregulated during infection, and  
213 PDGF-AB/BB was downregulated (Fig. 7B). There was a significant INF $\alpha$ -2 release by the  
214 WSN-infected HTECs at 96 h PI ( $P < 0.0005$ , vs mock) and by pH1N1-infected cells at 120 h PI  
215 ( $P < 0.005$ , as compared with that of mock-infected cells and H3N2  $P < 0.05$ ) (Fig. 8A) with  
216 no significant release of INF- $\gamma$  among the three viruses (Fig. 8B). HTEC infected with H3N2  
217 showed an early, abrupt, and strong release of TNF- $\alpha$  at 24, 96, and 120 h PI ( $P < 0.05$ ,  $< 0.005$ ,  
218 and  $< 0.05$ , respectively), whereas pH1N1 cause delayed peak at 120 h pi ( $P < 0.0005$ , vs. mock-  
219 infected cells) (Fig. 8C). This indicate that HTECs infected with IVs failed to evoke an early  
220 interferon response, but the induction of TNF- $\alpha$  may play a pathologic role. IL-1R-1 exhibited  
221 delayed release in cells infected with pH1N1 at 120 h PI ( $P < 0.005$ ), which occurred in higher  
222 concentrations than that in H3N2-infected cells earlier at 24 h ( $P < 0.05$ ) (Fig. 8D). In contrast,  
223 the IL-1a levels released in WSN-infected cells were lower than that in H3N2-infected cells at 24  
224 h PI ( $P < 0.05$ ) (Fig. 8E). While IL-1 $\beta$  was significantly induced only by pH1N1- at 72 h PI (Fig.  
225 FI). IL-6 exhibited early release from the HTECs infected with H3N2 at 24 and 48 h PI ( $P < 0.05$   
226 for both comparisons) while pH1N1 caused significant IL-6 release at 48, 72, and 120 h PI ( $P <$   
227  $0.05$ ,  $0.005$ , and  $0.05$ , respectively) with minor changes by WSN, as compared with that of  
228 pH1N1-infected cells at 72 h PI ( $P < 0.05$ ) (Fig. 8G). There were no significant changes in IL-7  
229 levels among the 3 viruses (Fig. 8H). While, IL-15 was significantly induced in H3N2-infected  
230 cells at 96 and 120 h PI ( $P < 0.005$  and  $0.0005$ , respectively) and higher in pH1N1-infected cells  
231 at 120 h PI ( $P < 0.05$ ) (Fig. 8I). The synergistic interaction between IL-6 and IL-15 suggests that  
232 IV-infected HTECs exacerbate clinical outcomes during IV infections. The H3N2 and pH1N1  
233 infected HTECs induced IP-10 (CXCL10) at 120 h PI ( $P < 0.005$  and  $0.05$ , respectively, vs.

234 mock infection), with hyperactivated proinflammatory IP-10 response by pH1N1 than H3N2 ( $P$   
235  $< 0.05$ ) (Fig. 8J). Unlike the previous cytokines, G-CSF was significantly induced by pH1N1 as  
236 early as at 72 h PI ( $P < 0.05$ ) and late by H3N2 at 120 h PI ( $P < 0.0005$ ) (Fig. 8K). However,  
237 GM-CSF levels were higher in H3N2-infected cells than in pH1N1-infected cells ( $P < 0.05$ ) and  
238 WSN-infected cells ( $P < 0.05$ ) at 24 and 96 h PI (Fig 8L). The release of G-CSF and GM-CSF  
239 from the HTECs indicates that the tonsils may contribute to the immune/inflammatory cascade  
240 induced early by H3N2 and after 4 days by pH1N1. The chemokine CCL2 (MCP-1) showed  
241 early increased by H3N2 ( $P < 0.05$ , vs. mock infection, and  $P < 0.05$  vs. pH1N1) at 24 h PI with  
242 fluctuating level at 48 and 72 h PI. While pH1N1 showed late peak at 120 h PI (Fig. 8M). There  
243 were no significant changes of either MIP1b or MIP1a levels with any of the IVs (Fig. 8N, O).  
244 While, the VEGF was upregulated by H3N2 and WSN at 24 h PI, as compared with that of  
245 mock-infected cells ( $P < 0.05$  and  $0.05$ , respectively), and higher than pH1N1 ( $P < 0.05$  and  
246  $0.05$ , respectively) at 48 h PI (Fig. 8P). This indicates that H3N2 enhances early healing and  
247 regeneration. HTECs infected with WSN released fractalkine (CX3CL1) at 24 h PI, with  
248 maximum increase at 48 h PI, in contrast with that of mock- and H3N2-infected cells ( $P <$   
249  $0.0005$  and  $0.005$ , respectively). However, H3N2-infected HTECs induced significantly higher  
250 fractalkine at 96 h PI and pH1N1 at 120 h PI (Fig. 8Q). There was a fluctuating release of the  
251 RANTES by H3N2 at 24 and 120 h PI ( $P < 0.0005$  and  $0.005$ , respectively), and late release by  
252 pH1N1 at 120 h PI ( $P < 0.05$ ) (Fig. 7R). None of the IVs induced significant levels of GRO in the  
253 HTECs (Fig. 7S). PDGF-AA was induced only at 48 h PI by H3N2 ( $P < 0.05$ ) with higher levels  
254 than that of pH1N1 ( $P < 0.05$ ) (Fig. 8T). While FGF-2, EGF and TGF- $\alpha$  induced at 24 h ( $P <$   
255  $0.05$ ) and 120 h ( $P < 0.0005$ ) PI by H3N2 with significant delayed exaggeration by pH1N1 at  
256 120 h PI ( $P < 0.05$ ) (Fig. 8U-W). Together, these findings indicate that HTECs play a distinct

257 role in the induction of various proinflammatory and chemoattractive cytokines during IV  
258 infection which fluctuates during infection and H3N2 induces an early response that persists,  
259 whereas pH1N1 induces a primarily late response in HTECs.

260

## 261 **DISCUSSION**

262 Cell cultures of HTECs yielded heterogeneous squamous epithelial cells with clear  
263 differentiation and keratin expression patterns that are consistent with those of previous studies  
264 (8, 36). By using a panel of antibodies specific to different keratins, we confirmed that the tonsil  
265 epithelium consists of both stratified surface and reticulated crypt epithelial cells. *In situ* staining  
266 of the tonsil epithelium suggests that expression of the simple epithelial keratins K18 and K8, as  
267 well as K19, are specific to the crypt epithelial cells (5). K8 conventionally partners with K18  
268 and was weakly expressed in keratinocytes of the surface tonsil epithelium but was strongly  
269 expressed in the reticulated crypts, specifically covering the upper layers of the crypts. Another  
270 cytokeratin that distinguishes the tonsillar crypts from surface epithelia is K19, which was  
271 variably expressed in the HTECs. K5 and K14 were strongly expressed in the surface epithelium.  
272 This suggests that our HTECs were highly differentiated and produced heterogeneous squamous  
273 cells, consisting of both surface stratified and crypt epithelial cells, consistent with those found in  
274 tonsil epithelial cells *in situ* (8, 37, 38). The stratified surface and reticulated epithelia cell  
275 populations within the HTECs contained large cytoplasm-to-nuclei ratios and heterogeneous  
276 squamous epithelial cells, further recapitulating human tonsil epithelial cells *in vivo*, with  
277 subpopulations of non-ciliated cells, few ciliated cells, and specialized cells with secretory  
278 functions.

279 Acquiring mutations and switching receptor-binding specificity between avian and human  
280 SA receptor preferences are key for IVs to transmit efficiently in humans and most likely occurs  
281 when adapting to new hosts (39, 40). We found that human-like  $\alpha$ 2,6-linked SA receptors  
282 predominated in the ciliated cells, and surface stratified epithelial cells contained abundant  
283 avian-like  $\alpha$ 2,3-linked SA receptors, which were more abundant and present on microvilli-  
284 containing reticular epithelial cells. Both  $\alpha$ 2,6-linked and  $\alpha$ 2,3-linked SA receptors were  
285 heterogeneously distributed. The HTEC surface and crypts were lined with pseudostratified  
286 columnar ciliated cells possessing both  $\alpha$ 2,6-linked and  $\alpha$ 2,3-linked SA receptors that were  
287 interrupted by patches of reticular epithelial cells.

288 IVs are transmitted by respiratory routes in humans and by the fecal–oral route in avian  
289 species. Human tonsils are located in the entrance of both the respiratory and digestive tracts,  
290 whereas avian tonsils are located only in the digestive tract (41). A typical feature of the tonsils  
291 is lymphocytic infiltration into the squamous epithelium of the crypts on its concave surface and  
292 the mucosal surface (42). We found the HTECs were permissive for the growth of both influenza  
293 A and B viruses. Heterogeneous variation occurred in the levels of immune mediators and cell  
294 death. A subset of cells, primarily ciliated cells, underwent apoptosis, but others, including non-  
295 ciliated cells, remained intact, despite being positive for IV nucleoprotein. Interestingly,  
296 colocalization occurred primarily with H3N2 in non-ciliated cells, whereas H1N1 mostly  
297 associated with ciliated cells.

298 Human innate and adaptive immune responses are activated shortly after IV infection (43).  
299 However, excessive or unbalanced immune responses can cause overproduction of both  
300 cytokines and chemokines, leading to severe inflammation and involving excessive recruitment  
301 of neutrophils and mononuclear cells at the site of infection, contributing to serious illness and

302 mortality (44, 45). Many activities of innate and adaptive immune cells are coordinated by  
303 cytokines (44, 46–48). IL-6, IL-1 $\alpha$ , IL-1 $\beta$ , IL-8, GM-CSF, and TNF- $\alpha$  are linked to protective  
304 Th1 responses (44, 49), effecting chemotaxis and activation of macrophages, neutrophils, and  
305 lymphocytes *in vivo*. The upregulation of these cytokines indicates that HTECs are an important  
306 source of proinflammatory cytokines in response to IV infection (48, 50). The tonsils provide  
307 defense against pathogens in the nasopharynx by infiltration of B and T lymphocytes into the  
308 heterogenous squamous epithelium of the crypts and the germinal center, in which B-memory  
309 cells are created and IgA secretory antibodies are produced (6). The germinal center reaction is  
310 critical for producing high-affinity and durable B-cell responses. Live attenuated IV vaccination  
311 provokes a germinal center reaction, which attracts B-cell clones, expanding the scope of  
312 protective antibodies caused by vaccinations (51). The excessive cytokine and chemokine  
313 response we observed in the HTECs indicates that the tonsils exacerbate virus-induced  
314 inflammation and pathology. Cytokine storm is associated with severe clinical outcomes during  
315 the course of IV infection (52–56). Several cytokines and chemokines, including VEGF,  
316 RANTES, MCP-1, IP-10, IL-8, IL-6, IL-1 $\alpha$ , IL-1 $\beta$ , GRO, INF- $\alpha$ 2, fractalkine, GM-CSF, TGF- $\alpha$ ,  
317 FGF-2, and EGF, were secreted from HTECs at significant concentrations, consistent with  
318 dynamic communication between the tonsils and the immune system response earlier with H3N2  
319 and later with pH1N1. High levels of IL-6 and IP-10 are linked to severe symptoms (57). The  
320 release of IP-10 from HTECs is also an important hallmark of seasonal IV infection, which can  
321 help clinicians make timely treatment decisions for patients with severe disease. Taken together,  
322 our findings demonstrate that several important cytokines are secreted from infected HTECs and  
323 that these cells are most likely to be the source of classic proinflammatory cytokines, such as IL-  
324 6 and TNF- $\alpha$ , which are elevated during systemic IV infections. The elicited production of the

325 proinflammatory cytokines IL-15 and IL-6 in HTECs, suggesting a key role for these  
326 interleukins in the pathogenesis of epithelial cell damage and sore throat inflammation (58).  
327 Therefore, the cytokines release in relation to clinical findings, disease severity, and outcomes of  
328 children with IVs infection are needed. Our finding highlights the role of tonsils as a source of  
329 the previously reported proinflammatory cytokines, TNF, IL-6, IFN- $\gamma$ 1, IFN- $\beta$ , IL-10, IL-8, and  
330 CXCL10, induced upon exposure to H3N2 (59). IV induction of IL-1 $\beta$  increases inflammation in  
331 lung cells; conversely, blockade of IL-1 $\beta$  signals with an IL-1 $\beta$  receptor antagonist or a  
332 neutralizing antibody alleviates inflammation (60), suggesting that IL-1 $\beta$  secretion by HTECs  
333 contributes to IV-induced inflammation. Thus, blockade of IL-1 $\beta$  signals can be a potential early  
334 therapeutic target for IV-induced inflammation (61). While IFN- $\gamma$  is a particularly important  
335 factor in antiviral responses, and lower levels of IFN- $\gamma$  confer weak antiviral ability (60), the  
336 lower levels of TNF- $\alpha$  and IFN- $\gamma$  in our HTECs model may indicate weak anti-infection ability  
337 and the severe flu symptoms in children (62). We noted that HTECs upregulate VEGF in  
338 response to IV infection. This suggests that VEGF may be an early marker of IV infection and  
339 that HTECs are an important source of VEGF. MCP-1 levels were especially higher in patients  
340 with severe pneumonia who developed respiratory failure. These findings suggest that MCP-1  
341 released by infected HTECs may contribute to the pathogenesis and severity of respiratory  
342 complications during IVs infection (63). While MIP-1 $\beta$  and IL-10 production is higher in fatal  
343 IV cases than in nonfatal cases (64). We did not observe any significant changes in MIP-1 $\beta$  in  
344 our HTEC model.

345

346 Our study reveals novel insights into the interplay between IVs and host signaling pathways  
347 in an underappreciated tissue such as the tonsils. The early release of cytokines and chemokines



348 upon IV infection indicates that the tonsils are an important primary site of IV infections.  
349 Whether tonsillectomy affects the response to IV infections or vaccination is currently unknown.  
350 Tonsillectomy is a common surgical procedure in children (65), when the immune system is  
351 critically developing (66–69). We found a significant association in both immunity and cytokine  
352 storm in the HTECs. However, whether IV causes severe disease in individuals with or without  
353 tonsils and the prevalence of IV infections in both subpopulations remain to be determined. IV  
354 infections are well characterized to cause diverse outcomes that can result in severe  
355 complications and high mortality in some populations and mild symptoms in others. Thus,  
356 elucidating the factors related to these diverse outcomes is sorely needed.

357 In conclusion, the well-differentiated HTEC culture system we generated provides a  
358 valuable *in vitro* model for studying the cellular tropism and infectivity of IVs in human tonsils  
359 and may be valuable for developing an effective universal vaccine and therapies against different  
360 strains of IVs. Our results implicate the human tonsillar crypt epithelium as a site for IV  
361 replication that is permissive for the growth of different IV A and B strains.

362

## 363 MATERIAL AND METHODS

364 **An air–liquid interface culture system for differentiated primary human tonsil epithelial**  
365 **cells.** Primary HTECs were purchased from ScienCell Research Laboratories and were seeded on  
366 type I collagen (Sigma)–coated flasks supplemented with modified bronchial epithelial cell  
367 serum-free growth medium (70). The cells were transferred to type IV collagen-coated Transwell  
368 polycarbonate membranes (24-well, 0.4  $\mu\text{m}$  pore size, Corning Costar) in a cell density of  
369  $2.5 \times 10^5$  cells/filter, with the air–liquid interface (ALI) medium supplemented with additives, as

370 previously described (71). After the HTECs reached complete confluence, the cells were  
371 maintained under ALI conditions for 4–5 weeks at 37°C in a humidified 5% CO<sub>2</sub> incubator.

372

373 **Morphological characterization and lectin staining of HTECs.** Slides containing the well-  
374 differentiated HTEC cultures were treated the same way in all staining procedures. For indirect  
375 immunofluorescence analysis, transwell membranes containing HTECs were fixed and  
376 permeabilized for 10 to 15 min with 100% chilled acetone and then blocked with 5% bovine  
377 serum albumin. Primary antibodies against K5, K14, K8/K18, K19, villin (Abcam), and  $\beta$ -  
378 tubulin (Invitrogen) were typically diluted 1:200 and incubated for 1 h at room temperature. All  
379 of the antibodies were diluted in 2% bovine serum albumin and incubated at room temperature  
380 for 1 h. The slides were then washed three times with phosphate-buffered saline (PBS) and  
381 incubated with corresponding secondary antibodies. Secondary antibodies comprised goat anti-  
382 mouse or anti-rabbit antibodies conjugated to Alexa 488, Alexa 594, or Alexa 633 (1:5,000, Life  
383 Technologies). The cells were washed with PBS three times and visualized with a fluorescence  
384 microscope. Lectin staining was performed by using SNA or MAAII (Vector Laboratories) (72).  
385 Biotinylated lectin binding was visualized by fluorescence and confocal laser microscopy of  
386 streptavidin-conjugated Daylight 488 (Vector Laboratories). Nuclei were stained with 4',6'-  
387 diamidino-2-phenylindole and were embedded with ProLong Gold mounting medium (Life  
388 Technologies). ImageJ/Fiji software (National Institutes of Health) was used with the maximum  
389 intensity projection filter to process and analyze the confocal images. All experiments were  
390 repeated three times, with six fields per culture.

391

392 **Scanning electron microscopy.** Scanning electron microscopy was performed as previously  
393 described (73). Briefly, cultured cells on membranes were fixed in 2.5% glutaraldehyde for 24 h  
394 and then treated with 1% osmium tetroxide for 2 h. This was followed by dehydration in an  
395 ascending series of ethanol and then dried with an E 3000 device (Polaron), adhered to stubs,  
396 sputter-coated, and examined under a scanning electron microscope (DSM940, Zeiss).

397

398 **Susceptibility of HTECs to IVs.** Primary HTECs were grown at the ALI and infected apically  
399 with different IVs at various MOIs (Table 1). Three human H3N2 viruses  
400 (A/SWITZERLAND/8060/2017, A/HONG KONG/4801/2014, and A/MEMPHIS/257/2019),  
401 one swine H3N2 virus (A/SWINE/OH/16TOSU4783/2016), two human H1N1 viruses  
402 (A/TENNESSEE/1-560/2009 and A/BRISBANE/59/2007), two swine H1N1 viruses  
403 (A/SWINE/MN/37866/1999 and A/SWINE/NC/18161/2002), one swine H1N2  
404 (A/SWINE/OH/09SW1486/2009), one avian virus (RGA/VIETNAM/1203/04), one influenza C  
405 virus (C/JOHANNESBURG/1/1966), and two influenza B viruses (egg-propagated  
406 B/BRISBANE/60/08 and cell-propagated B/BRISBANE/60/08) were used. We used  
407 A/RG/WSN/33 as a control virus because of its highly tropic and pathogenic effects.

408

409 **Viral replication kinetic in the well differentiated HTECs.** To measure viral growth kinetics,  
410 three IV subtypes representing pH1N1 (A/TENNESSEE/1-560/2009), H3N2  
411 (A/MEMPHIS/257/2019), and A/RG/WSN/33 were used. Well-differentiated HTECs  
412 (approximately  $6 \times 10^5$  cells/filter) were washed three times with PBS and inoculated with IVs  
413 from the apical side at a MOI of 0.1 for multiple-step kinetics and an MOI of 1 for single-step  
414 kinetics. After 2 h of incubation at 37°C, HTECs were rinsed with PBS three times to remove

415 unbound viral particles, and fresh ALI medium was added. Infected HTECs were maintained  
416 under ALI conditions at 37°C in 5% CO<sub>2</sub>. At different time points, 100 µL of DMEM was added  
417 to the apical surface, and the cultures were incubated for 30 min at 37°C. The harvested cells  
418 were collected at different times post infection. The infectivity of the viruses was evaluated by  
419 titrating the viruses by plaque assay or 50% tissue culture infectious dose.

420

421 **Immunofluorescence analysis for colocalization of viral protein.** To determine the  
422 colocalization of viral proteins in HTECs, whole-filter cell cultures were fixed in 100% chilled  
423 acetone, blocked with 5% acetone, and incubated with primary monoclonal antibodies against  
424 influenza nucleoprotein (1:5,000) at room temperature for 30 min. The cells were then washed  
425 three times in PBS and stained with secondary goat anti-mouse Alexa 488 or Alexa 594  
426 antibodies (1:5,000) (Molecular Probes) for 1 h in the dark. The cells were washed with PBS  
427 three times and examined with a fluorescence microscope (Nikon E400) or confocal laser  
428 microscope (Life Science Microscope, Keyence Corporation of America).

429

430 **Cytokine quantification.** Multiplexed cytokine assays were performed according to the  
431 manufacturer instructions by using a Bio-Plex Pro Human cytokine screening panel (Biorad)  
432 containing 48 human cytokines, and the spectral intensities were quantified with a Luminex  
433 instrument. Cytokine concentrations were calculated by interpolating values from a standard  
434 curve via 5PL curve fitting. Samples with values below the detection limit were assigned a value  
435 of 1 to enable the use of a log scale for calculating fold changes and graphing. IL-11 was  
436 quantified by using a Human IL-11 Quantikine ELISA Kit according to manufacturer  
437 instructions (R&D Systems). Statistical analysis was performed on log<sub>10</sub>-transformed values with

438 two-way ANOVA tests and Tukey correction. To identify the cytokines secreted by uninfected  
439 HTECs, the following criteria were used: < 10-fold increased cytokine signal at different time  
440 points compared to media. To identify significantly increased cytokine concentrations upon  
441 infection, an adjusted *P* value (< 0.01) between the cytokine signals at different time points vs.  
442 those of uninfected controls was used.

443

444 **Statistical analyses.** All data shown are means ± standard error. All statistical analyses were  
445 performed with Prism 9 software (GraphPad Software).

446

#### 447 **Acknowledgments:**

448 We are grateful to the imaging help provided by Ryan Kelly, from the Keyence Corporation of  
449 America. We are thankful for Bindumadhav Marathe and John Franks for their technical help,  
450 for Dr. Cam Robinson for his help in scanning microscopy, and for the excellent scientific  
451 editing of the manuscript by Nisha Badders.

452

#### 453 **Author Contributions**

454 F. O. performed the experiments, analyzed the data, and wrote the manuscript; A.S. analyzed the  
455 data; R. W. supervised the study; R.J.W. supervised the study, analyzed the data, Funding, and  
456 wrote the manuscript. All authors have read and agreed to the published version of the  
457 manuscript.

458

#### 459 **Funding**

460 This study was supported by the National Institute of Allergy and Infectious Diseases, NIH,  
461 under CEIRS Contract HHSN272201400006C. The content is solely the responsibility of the  
462 authors and does not necessarily represent the official views of the National Institutes of Health.

463

464

465

466

467

## 468 **REFERENCES**

- 469 1. CDC. 2019. Disease Burden of Influenza  
470 <https://www.cdc.gov/flu/about/burden/index.html>  
471 <https://www.cdc.gov/flu/about/burden/index.html>.
- 472 2. Paules CI, Sullivan SG, Subbarao K, Fauci AS. 2018. Chasing Seasonal Influenza — The  
473 Need for a Universal Influenza Vaccine. *N Engl J Med* 378:7–9.
- 474 3. Okda FA, Griffith E, Sakr A, Nelson E, Webby R. 2020. New Diagnostic Assays for  
475 Differential Diagnosis Between the Two Distinct Lineages of Bovine Influenza D Viruses  
476 and Human Influenza C Viruses. *Front Vet Sci* 7:605704.
- 477 4. Erbeding EJ, Post DJ, Stemmy EJ, Roberts PC, Augustine AD, Ferguson S, Paules CI,  
478 Graham BS, Fauci AS. 2018. A Universal Influenza Vaccine: The Strategic Plan for the  
479 National Institute of Allergy and Infectious Diseases. *J Infect Dis* 218:347–354.
- 480 5. Pegtel DM, Middeldorp J, Thorley-Lawson DA. 2004. Epstein-Barr virus infection in ex

- 481 vivo tonsil epithelial cell cultures of asymptomatic carriers. *J Virol* 78:12613–12624.
- 482 6. Scadding GK. 1990. Immunology of the tonsil: a review. *J R Soc Med* 83:104–107.
- 483 7. Perry ME. 1994. The specialised structure of crypt epithelium in the human palatine tonsil  
484 and its functional significance. *J Anat* 185 ( Pt 1:111–127).
- 485 8. Gotoh K, Ito Y, Maruo S, Takada K, Mizuno T, Teranishi M, Nakata S, Nakashima T,  
486 Iwata S, Goshima F, Nakamura S, Kimura H. 2011. Replication of Epstein-Barr virus  
487 primary infection in human tonsil tissue explants. *PLoS One* 6:e25490.
- 488 9. Wagar LE, Salahudeen A, Constantz CM, Wendel BS, Lyons MM, Mallajosyula V, Jatt  
489 LP, Adamska JZ, Blum LK, Gupta N, Jackson KJL, Yang F, Röltgen K, Roskin KM,  
490 Blaine KM, Meister KD, Ahmad IN, Cortese M, Dora EG, Tucker SN, Sperling AI, Jain  
491 A, Davies DH, Felgner PL, Hammer GB, Kim PS, Robinson WH, Boyd SD, Kuo CJ,  
492 Davis MM. 2021. Modeling human adaptive immune responses with tonsil organoids. *Nat*  
493 *Med* <https://doi.org/10.1038/s41591-020-01145-0>.
- 494 10. Zhang L-Y, Zhong L, David M, Cervin A. 2017. Tonsillectomy or tonsillotomy? A  
495 systematic review for paediatric sleep-disordered breathing. *Int J Pediatr*  
496 *Otorhinolaryngol* 103:41–50.
- 497 11. Gillum BS, Graves EJ, Kozak LJ. 1996. Trends in hospital utilization: United States,  
498 1988-92. *Vital Heal Stat Ser 13 Data Heal Resour Util* 13.
- 499 12. Millington AJ, Phillips JS. 2014. Current trends in tonsillitis and tonsillectomy. *Ann R*  
500 *Coll Surg Engl* 96:586–589.

- 501 13. Setabutr D, Adil EA, Adil TK, Carr MM. 2011. Emerging trends in tonsillectomy.  
502 Otolaryngol - Head Neck Surg 145:223–229.
- 503 14. Sun W, Han X, Wu S, Yang C. 2016. Tonsillectomy and the risk of inflammatory bowel  
504 disease: A systematic review and meta-analysis. J Gastroenterol Hepatol 31:1085–1094.
- 505 15. Cooper C, Pippard EC, Sharp H, Wickham C, Chamberlain MA, Barker DJP. 1989. Is  
506 Behcet's disease triggered by childhood infection? Ann Rheum Dis 48:421–423.
- 507 16. Wyatt H V. 1990. Incubation of poliomyelitis as calculated from the time of entry into the  
508 central nervous system via the peripheral nerve pathways. Rev Infect Dis 12:547–556.
- 509 17. Ogra PL. 1971. Effect of tonsillectomy and adenoidectomy on nasopharyngeal antibody  
510 response to poliovirus. N Engl J Med 284:59–64.
- 511 18. ANDERSON GW, ANDERSON G, SKAAR AE, SANDLER F. 1950. The risk of  
512 poliomyelitis after tonsillectomy. Ann Otol Rhinol Laryngol 59:602–613.
- 513 19. Byars SG, Stearns SC, Boomsma JJ. 2018. Association of long-term risk of respiratory,  
514 allergic, and infectious diseases with removal of adenoids and tonsils in childhood. JAMA  
515 Otolaryngol - Head Neck Surg 144:594–603.
- 516 20. Mészáros D, Dharmage SC, Matheson MC, Venn A, Wharton CL, Johns DP, Abramson  
517 MJ, Giles GG, Hopper JL, Walters EH. 2010. Poor lung function and tonsillectomy in  
518 childhood are associated with mortality from age 18 to 44. Respir Med 104:808–815.
- 519 21. Ji J, Sundquist J, Sundquist K. 2016. Tonsillectomy associated with an increased risk of



- 520 autoimmune diseases: A national cohort study. *J Autoimmun* 72:1–7.
- 521 22. Vestergaard H, Westergaard T, Wohlfahrt J, Hjalgrim H, Melbye M. 2010. Tonsillitis,  
522 tonsillectomy and Hodgkin’s lymphoma. *Int J cancer* 127:633–637.
- 523 23. Brasky TM, Bonner MR, Dorn J, Marhsall JR, Vena JE, Brasure JR, Freudenheim JL.  
524 2009. Tonsillectomy and breast cancer risk in the Western New York Diet Study. *Cancer*  
525 *Causes Control* 20:369–374.
- 526 24. Sun L-M, Chen H-J, Li T-C, Sung F-C, Kao C-H. 2015. A nationwide population-based  
527 cohort study on tonsillectomy and subsequent cancer incidence. *Laryngoscope* 125:134–  
528 139.
- 529 25. Janszky I, Mukamal KJ, Dalman C, Hammar N, Ahnve S. 2011. Childhood  
530 appendectomy, tonsillectomy, and risk for premature acute myocardial infarction--a  
531 nationwide population-based cohort study. *Eur Heart J* 32:2290–2296.
- 532 26. Stenfeldt C, Diaz-San Segundo F, de los Santos T, Rodriguez LL, Arzt J. 2016. The  
533 Pathogenesis of Foot-and-Mouth Disease in Pigs. *Front Vet Sci* 3:41.
- 534 27. Ruggiero F, Carbone D, Mugavero R, Cura F, Baggi L, Arcuri C, Nardone M, Gaudio  
535 RM, Gatto R, Scapoli L, Carinci F. 2018. Human papilloma virus in the tonsillar  
536 microbiota of an Afghan population group. *J Biol Regul Homeost Agents* 32:191–196.
- 537 28. Soare AY, Durham ND, Gopal R, Tweel B, Hoffman KW, Brown JA, O’Brien M,  
538 Bhardwaj N, Lim JK, Chen BK, Swartz TH. 2019. P2X Antagonists Inhibit HIV-1  
539 Productive Infection and Inflammatory Cytokines Interleukin-10 (IL-10) and IL-1 $\beta$  in a

- 540 Human Tonsil Explant Model. *J Virol* 93.
- 541 29. Hasegawa M, Hashimoto K, Morozumi M, Ubukata K, Takahashi T, Inamo Y. 2010.  
542 Spontaneous pneumomediastinum complicating pneumonia in children infected with the  
543 2009 pandemic influenza A (H1N1) virus. *Clin Microbiol Infect* 16:195–199.
- 544 30. Kamigaki T, Oshitani H. 2009. Epidemiological characteristics and low case fatality rate  
545 of pandemic (H1N1) 2009 in Japan. *PLoS Curr* 1:RRN1139.
- 546 31. García-Ramírez RA, Ramírez-Venegas A, Quintana-Carrillo R, Camarena AE, Falfán-  
547 Valencia R, Mejía-Aranguré JM. 2015. TNF, IL6, and IL1B polymorphisms are  
548 associated with severe influenza a (H1N1) virus infection in the Mexican Population.  
549 *PLoS One* 10.
- 550 32. Murray CJL, Lopez AD, Chin B, Feehan D, Hill KH. 2006. Estimation of potential global  
551 pandemic influenza mortality on the basis of vital registry data from the 1918–20  
552 pandemic: a quantitative analysis. *Lancet* 368:2211–2218.
- 553 33. Ghedin E, Sengamalay NA, Shumway M, Zaborsky J, Feldblyum T, Subbu V, Spiro DJ,  
554 Sitz J, Koo H, Bolotov P, Dernovoy D, Tatusova T, Bao Y, St George K, Taylor J,  
555 Lipman DJ, Fraser CM, Taubenberger JK, Salzberg SL. 2005. Large-scale sequencing of  
556 human influenza reveals the dynamic nature of viral genome evolution. *Nature* 437:1162–  
557 1166.
- 558 34. Loo Y-M, Gale M. 2007. Fatal immunity and the 1918 virus. *Nature* 445:267–268.
- 559 35. Estella A. 2011. Cytokine levels in bronchoalveolar lavage and serum in 3 patients with

- 560 2009 Influenza A(H1N1)v severe pneumonia. *J Infect Dev Ctries* 5.
- 561 36. Guidry JT, Myers JE, Bienkowska-Haba M, Songock WK, Ma X, Shi M, Nathan CO,  
562 Bodily JM, Sapp MJ, Scott RS. 2019. Inhibition of Epstein-Barr Virus Replication in  
563 Human Papillomavirus-Immortalized Keratinocytes. *J Virol* 93.
- 564 37. Clark MA, Wilson C, Sama A, Wilson JA, Hirst BH. 2000. Differential cytokeratin and  
565 glycoconjugate expression by the surface and crypt epithelia of human palatine tonsils.  
566 *Histochem Cell Biol* 114:311–321.
- 567 38. Mischke D, Genka T, Wille G, Lobeck H, Wild AG. 1991. Keratins as molecular markers  
568 of epithelial differentiation: differential expression in crypt epithelium of human palatine  
569 tonsils. *Ann Otol Rhinol Laryngol* 100:372–377.
- 570 39. Maines TR, Chen LM, Matsuoka Y, Chen H, Rowe T, Ortin J, Falcón A, Hien NT, Mai  
571 LQ, Sedyaningsih ER, Harun S, Tumpey TM, Donis RO, Cox NJ, Subbarao K, Katz JM.  
572 2006. Lack of transmission of H5N1 avian-human reassortant influenza viruses in a ferret  
573 model. *Proc Natl Acad Sci U S A* 103:12121–12126.
- 574 40. Matrosovich M, Tuzikov A, Bovin N, Gambaryan A, Klimov A, Castrucci MR, Donatelli  
575 I, Kawaoka Y. 2000. Early Alterations of the Receptor-Binding Properties of H1, H2, and  
576 H3 Avian Influenza Virus Hemagglutinins after Their Introduction into Mammals. *J Virol*  
577 74:8502–8512.
- 578 41. Combes JD, Clavel C, Dalstein V, Gheit T, Clifford GM, Tommasino M, Franceschi S,  
579 Lacau St Guily J. 2018. Human papillomavirus detection in gargles, tonsil brushings, and

- 580 frozen tissues in cancer-free patients. *Oral Oncol* 82:34–36.
- 581 42. Kidshealth. 2013. Tonsils and tonsillectomies.
- 582 43. Bellinghausen C, Gulraiz F, Heinzmann ACA, Dentener MA, Savelkoul PHM, Wouters  
583 EF, Rohde GG, Stassen FR. 2016. Exposure to common respiratory bacteria alters the  
584 airway epithelial response to subsequent viral infection. *Respir Res* 17.
- 585 44. Betakova T, Kostrabova A, Lachova V, Turianova L. 2017. Cytokines Induced During  
586 Influenza Virus Infection. *Curr Pharm Des* 23:2616–2622.
- 587 45. Smith MW, Schmidt JE, Rehg JE, Orihuela CJ, McCullers JA. 2007. Induction of pro- and  
588 anti-inflammatory molecules in a mouse model of pneumococcal pneumonia after  
589 influenza. *Comp Med* 57:82–89.
- 590 46. Vaday GG, Lider O. 2000. Extracellular matrix moieties, cytokines, and enzymes:  
591 dynamic effects on immune cell behavior and inflammation. *J Leukoc Biol* 67:149–159.
- 592 47. Tumpey TM, García-Sastre A, Taubenberger JK, Palese P, Swayne DE, Pantin-Jackwood  
593 MJ, Schultz-Cherry S, Solórzano A, Van Rooijen N, Katz JM, Basler CF. 2005.  
594 Pathogenicity of Influenza Viruses with Genes from the 1918 Pandemic Virus: Functional  
595 Roles of Alveolar Macrophages and Neutrophils in Limiting Virus Replication and  
596 Mortality in Mice. *J Virol* 79:14933–14944.
- 597 48. McNamee LA, Harmsen AG. 2006. Both influenza-induced neutrophil dysfunction and  
598 neutrophil-independent mechanisms contribute to increased susceptibility to a secondary  
599 *Streptococcus pneumoniae* infection. *Infect Immun* 74:6707–6721.

- 600 49. Robinson KM, McHugh KJ, Mandalapu S, Clay ME, Lee B, Scheller E V., Enelow RI,  
601 Chan YR, Kolls JK, Alcorn JF. 2014. Influenza A virus exacerbates staphylococcus aureus  
602 pneumonia in mice by attenuating antimicrobial peptide production. *J Infect Dis* 209:865–  
603 875.
- 604 50. Didierlaurent A, Goulding J, Patel S, Snelgrove R, Low L, Bebien M, Lawrence T, Van  
605 Rijt LS, Lambrecht BN, Sirard JC, Hussell T. 2008. Sustained desensitization to bacterial  
606 Toll-like receptor ligands after resolution of respiratory influenza infection. *J Exp Med*  
607 205:323–329.
- 608 51. Turner JS, Zhou JQ, Han J, Schmitz AJ, Rizk AA, Alsoussi WB, Lei T, Amor M,  
609 McIntire KM, Meade P, Strohmeier S, Brent RI, Richey ST, Haile A, Yang YR, Klebert  
610 MK, Suessen T, Teefey S, Presti RM, Krammer F, Kleinstein SH, Ward AB, Ellebedy  
611 AH. 2020. Human germinal centres engage memory and naive B cells after influenza  
612 vaccination. *Nature* 586:127–132.
- 613 52. Wang C, Yu H, Horby PW, Cao B, Wu P, Yang S, Gao H, Li H, Tsang TK, Liao Q, Gao  
614 Z, Ip DKM, Jia H, Jiang H, Liu B, Ni MY, Dai X, Liu F, Van Kinh N, Liem NT, Hien TT,  
615 Li Y, Yang J, Wu JT, Zheng Y, Leung GM, Farrar JJ, Cowling BJ, Uyeki TM, Li L. 2014.  
616 Comparison of patients hospitalized with influenza A subtypes H7N9, H5N1, and 2009  
617 pandemic H1N1. *Clin Infect Dis an Off Publ Infect Dis Soc Am* 58:1095–1103.
- 618 53. Hung IF, To KK, Lee C-K, Lee K-L, Chan K, Yan W-W, Liu R, Watt C-L, Chan W-M,  
619 Lai K-Y, Koo C-K, Buckley T, Chow F-L, Wong K-K, Chan H-S, Ching C-K, Tang BS,  
620 Lau CC, Li IW, Liu S-H, Chan K-H, Lin C-K, Yuen K-Y. 2011. Convalescent plasma

- 621 treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009  
622 virus infection. *Clin Infect Dis an Off Publ Infect Dis Soc Am* 52:447–456.
- 623 54. Bradley-Stewart A, Jolly L, Adamson W, Gunson R, Frew-Gillespie C, Templeton K,  
624 Aitken C, Carman W, Cameron S, McSharry C. 2013. Cytokine responses in patients with  
625 mild or severe influenza A(H1N1)pdm09. *J Clin Virol Off Publ Pan Am Soc Clin Virol*  
626 58:100–107.
- 627 55. Wu C, Lu X, Wang X, Jin T, Cheng X, Fang S, Wang X, Ma H, Zhang R, Cheng J. 2013.  
628 Clinical symptoms, immune factors, and molecular characteristics of an adult male in  
629 Shenzhen, China infected with influenza virus H5N1. *J Med Virol* 85:760–768.
- 630 56. de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJD, Chau TNB, Hoang DM,  
631 Chau NVV, Khanh TH, Dong VC, Qui PT, Cam B Van, Ha DQ, Guan Y, Peiris JSM,  
632 Chinh NT, Hien TT, Farrar J. 2006. Fatal outcome of human influenza A (H5N1) is  
633 associated with high viral load and hypercytokinemia. *Nat Med* 12:1203–1207.
- 634 57. Chi Y, Zhu Y, Wen T, Cui L, Ge Y, Jiao Y, Wu T, Ge A, Ji H, Xu K, Bao C, Zhu Z, Qi X,  
635 Wu B, Shi Z, Tang F, Xing Z, Zhou M. 2013. Cytokine and chemokine levels in patients  
636 infected with the novel avian influenza A (H7N9) virus in China. *J Infect Dis* 208:1962–  
637 1967.
- 638 58. Chiaretti A, Pulitanò S, Barone G, Ferrara P, Romano V, Capozzi D, Riccardi R. 2013.  
639 IL-1 $\beta$  and IL-6 Upregulation in Children with H1N1 Influenza Virus Infection. *Mediators*  
640 *Inflamm* 2013:495848.

- 641 59. Nguyen TH, McAuley JL, Kim Y, Zheng MZ, Gherardin NA, Godfrey DI, Purcell DF,  
642 Sullivan LC, Westall GP, Reading PC, Kedzierska K, Wakim LM. 2021. Influenza, but  
643 not SARS-CoV-2, infection induces a rapid interferon response that wanes with age and  
644 diminished tissue-resident memory CD8<sup>+</sup> T cells. *Clin & Transl Immunol* 10:e1242.
- 646 60. Bian J-R, Nie W, Zang Y-S, Fang Z, Xiu Q-Y, Xu X-X. 2014. Clinical aspects and  
647 cytokine response in adults with seasonal influenza infection. *Int J Clin Exp Med* 7:5593–  
648 5602.
- 649 61. Kim KS, Jung H, Shin IK, Choi B-R, Kim DH. 2015. Induction of interleukin-1 beta (IL-  
650 1 $\beta$ ) is a critical component of lung inflammation during influenza A (H1N1) virus  
651 infection. *J Med Virol* 87:1104–1112.
- 652 62. Li W, Liu L-F, Xu J-L, Shang S-Q. 2020. Epidemiological and Immunological Features of  
653 Influenza Viruses in Hospitalized Children with Influenza Illness in Hangzhou. *Fetal*  
654 *Pediatr Pathol* 39:21–28.
- 655 63. Takano T, Tajiri H, Kashiwagi Y, Kimura S, Kawashima H. 2011. Cytokine and  
656 chemokine response in children with the 2009 pandemic influenza A (H1N1) virus  
657 infection. *Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol* 30:117–120.
- 658 64. Wang Z, Zhang A, Wan Y, Liu X, Qiu C, Xi X, Ren Y, Wang J, Dong Y, Bao M, Li L,  
659 Zhou M, Yuan S, Sun J, Zhu Z, Chen L, Li Q, Zhang Z, Zhang X, Lu S, Doherty PC,  
660 Kedzierska K, Xu J. 2014. Early hypercytokinemia is associated with interferon-induced  
661 transmembrane protein-3 dysfunction and predictive of fatal H7N9 infection. *Proc Natl*

- 662 Acad Sci U S A 111:769–774.
- 663 65. Jones GH, Burnside G, McPartland J, Markey A, Fallon M, De S. 2018. Is tonsillectomy  
664 mandatory for asymmetric tonsils in children? A review of our diagnostic tonsillectomy  
665 practice and the literature. *Int J Pediatr Otorhinolaryngol* 110:57–60.
- 666 66. West LJ. 2002. Defining critical windows in the development of the human immune  
667 system. *Hum Exp Toxicol* 21:499–505.
- 668 67. Goenka A, Kollmann TR. 2015. Development of immunity in early life. *J Infect* 71 Suppl  
669 1:S112-20.
- 670 68. Dowling DJ, Levy O. 2014. Ontogeny of early life immunity. *Trends Immunol* 35:299–  
671 310.
- 672 69. Sharma AA, Jen R, Butler A, Lavoie PM. 2012. The developing human preterm neonatal  
673 immune system: a case for more research in this area. *Clin Immunol* 145:61–68.
- 674 70. Lam E, Ramke M, Groos S, Warnecke G, Heim A. 2011. A differentiated porcine  
675 bronchial epithelial cell culture model for studying human adenovirus tropism and  
676 virulence. *J Virol Methods* 178:117–123.
- 677 71. Dijkman R, Jebbink MF, Koekkoek SM, Deijs M, Jónsdóttir HR, Molenkamp R, Ieven M,  
678 Goossens H, Thiel V, van der Hoek L. 2013. Isolation and characterization of current  
679 human coronavirus strains in primary human epithelial cell cultures reveal differences in  
680 target cell tropism. *J Virol* 87:6081–6090.



- 681 72. Wu N-H, Meng F, Seitz M, Valentin-Weigand P, Herrler G. 2015. Sialic acid-dependent  
682 interactions between influenza viruses and *Streptococcus suis* affect the infection of  
683 porcine tracheal cells. *J Gen Virol* 96:2557–2568.
- 684 73. Pringproa K, Rohn K, Kummerfeld M, Wewetzer K, Baumgärtner W. 2010. Theiler's  
685 murine encephalomyelitis virus preferentially infects immature stages of the murine  
686 oligodendrocyte precursor cell line BO-1 and blocks oligodendrocytic differentiation in  
687 vitro. *Brain Res* 1327:24–37.
- 688 74. Roberts S, Evans D, Mehanna H, Parish JL. 2019. Modelling human papillomavirus  
689 biology in oropharyngeal keratinocytes. *Philos Trans R Soc B Biol Sci* 374.

**TABLE 1** Susceptibility of HTECs to different IVs.

Virus	24 h post infection			48 h post infection		
	HA <sup>a</sup>	MFI <sup>b</sup>	PFU <sup>c</sup>	HA <sup>a</sup>	MFI <sup>b</sup>	PFU <sup>c</sup>
A/SWITZERLAND/8060/2017(H3N2)	N	3725	$6.0 \times 10^5$	N	4120	$2.1 \times 10^6$
A/HONG KONG/4801/2014 (H3N2)	64	17 890	$3.0 \times 10^5$	64	20 198	$4.7 \times 10^6$
A/MEMPHIS/257/2019 (H3N2)	64	20 156	$1.2 \times 10^6$	128	23 876	$6.8 \times 10^6$
A/SWINE/OH/16TOSU4783/2016 (H3N2)	32	4993.5	$2.0 \times 10^4$	32	5321	$4.7 \times 10^4$
A/TENNESSEE/1-560/2009 (H1N1)	256	18 770	$3.4 \times 10^7$	256	19 064	$4.2 \times 10^7$
A/BRISBANE/59/2007 (H1N1)	64	22 134	$2.0 \times 10^6$	64	21 350	$3.0 \times 10^6$
A/SWINE/MN/37866/1999 (H1N1)	64	20 882	$1.5 \times 10^5$	32	21 071	$2.6 \times 10^5$
A/SWINE/NC/18161/2002 (H1N1)	32	5445.	$2.0 \times 10^4$	32	5046	$1.2 \times 10^5$
A/SWINE/OH/09SW1486/2009 (H1N2)	16	5235	$3.5 \times 10^4$	32	5650	$7.0 \times 10^5$
RGA/VIETNAM/1203/04 (H5N1)	N	6900	$1.3 \times 10^5$	N	6440	$4.1 \times 10^5$
C/JOHANNESBURG/1/1966	N	450	– <sup>d</sup>	N	1072	
B/BRISBANE/60/08 (EGG)	64	3704	$5.6 \times 10^5$	64	4250	$4.2 \times 10^5$
B/BRISBANE/60/08 (CELL)	32	2225.5	$3.0 \times 10^5$	32	3420	$2.5 \times 10^4$
A/RG/WSN/33	64	191340	$2.7 \times 10^7$	128	23 498	$7.3 \times 10^7$

<sup>a</sup>HA, hemagglutinin assay. <sup>b</sup>MFI, mean fluorescence intensity. <sup>c</sup>PFU, plaque-forming unit. <sup>d</sup>The symbol “–” means undetermined.

## Figure Legends:

**FIG 1** Tonsillectomy trends in the United States and heterogeneity by age. (A) Trends of patients receiving tonsillectomies (red) vs. those who did not (black) in the United States from 1960 to 2020. (B) The tonsils are located in the nasopharynx of humans. (C) Graphical illustration of the percentage of tonsillectomies performed per year and increased heterogeneity by age. Each color represents the decade of childhood tonsillectomy and subsequent growth until 2020. Black represents the populations with intact tonsils.

**FIG 2** Characterization of well-differentiated human tonsil epithelial cells. (A) Phase contrast microscopy images of day 10 human tonsillar epithelial cell (HTEC) cultures at the air-liquid interface reveals well-differentiated epithelial cells of different sizes, types, and cytoplasm-to-nucleus ratios. (B) Scanning electron micrograph illustrating the apical surface of the HTECs, which contain few ciliated epithelial cells and more microvilli. Scale bars = 5  $\mu\text{m}$ .

**FIG 3** Structure of the tonsil tissue and keratin expression in HTECs. A schematic of the tonsil structure in the left side adapted from (74) and has been modified. In the right side (A) Confocal microscopy showing that the tonsillar extracellular epithelial surface ( $\text{K5/K14}^+$ ) contains few ciliated cells ( $\beta\text{-tubulin}^+$ ) and (B) that the crypts ( $\text{K8/18}^+$  and  $\text{K19}^+$ ) have more villi and microvilli than cilia. Cells were fixed with chilled acetone and stained with monoclonal antibodies against K5, K14, K18, K19,  $\beta\text{-tubulin}$ , and villin. Colocalization was determined by using ImageJ and calculated by the Pearson correlation ( $R$ ).

**FIG 4** Lectin and keratin staining of human tonsillar epithelial cells. (A) The surface stratified epithelium (K5/K14<sup>+</sup>) is richer in  $\alpha$ 2,6-linked SA receptors (SNA<sup>+</sup>) than in avian-like  $\alpha$ 2,3-linked SA receptors (MAII<sup>+</sup>). (B) The reticular crypts (K19<sup>+</sup> and K8/18<sup>+</sup>) are richer in  $\alpha$ 2,3-linked SA receptors (MAII<sup>+</sup>) than in  $\alpha$ 2,6-linked SA receptors (SNA<sup>+</sup>). (C) Lectin staining of the distributed cilia. The cells were fixed with chilled acetone and stained with monoclonal antibodies against K5, K14, K18, K19,  $\beta$ -tubulin, and villin. Colocalization was determined by using ImageJ and calculated by the Pearson correlation (*R*).


**FIG 5** (A) Single-step H1N1, H3N2, and WSN (MOI 1) replication kinetics in HTECs. (B) Multiple-step H1N1, H3N2, and WSN (MOI 0.1) replication kinetics in HTECs. Well-differentiated HTECs were inoculated with IVs on the apical side. IVs released from the apical side were harvested at different time points and titrated by plaque assay. The means  $\pm$  SEM of five HTEC cultures from three independent experiments are shown. Statistical significance was determined by two-way ANOVA and Tukey posthoc analysis, comparing each set of results to those for the mock cells. \**P* < 0.05; \*\**P* < 0.01; \*\*\**P* < 0.001; \*\*\*\**P* < 0.0001.

**FIG 6** Colocalization of IV nucleoprotein staining in HTECs. (A) H3N2 colocalized more with the tonsillar crypts than with surfaces. (B) H1N1 associated more with the ciliated and surface stratified epithelia than with the crypts. The crypts remained intact despite infection. Well-differentiated HTECs were infected with IVs on the apical side at a MOI of 0.1. Epithelial cells were fixed with chilled acetone at days 2, 5, 7, and 10 PI and stained with monoclonal antibodies against K5, K14, K18, K19,  $\beta$ -tubulin, and IV nucleoprotein. Colocalization was determined by using ImageJ and calculated by the Pearson correlation (*R*).


**FIG 7** Heat map showing the cytokine immune response in HTECs at different times post infection. The values shown are fold changes from mock-infected cells. (A) H3N2. (B) pH1N1.

**FIG 8** Cytokine secretion from HTECs upon infection with pH1N1, H3N2, and WSN IVs. The mean cytokine concentrations (pg/mL, log) detected at the indicated time points and infection conditions are shown ( $n = 5$  replicates). Statistical significance was determined by two-way ANOVA and Tukey posthoc analysis, comparing each set of results to those of the mock virus.  $*P < 0.05$ ;  $**P < 0.01$ ;  $***P < 0.001$ ;  $****P < 0.0001$ .


1.A




1.B




1.C




2.A




2.B







3.A

K5  $\beta$  tubulin




K14  $\beta$  tubulin




3.B


$\beta$  tubulin K8/18





$\beta$  tubulin K19



Anti-Villin K8/18



Anti-Villin K19






## 4.A


SNA K5

92.46%




SNA K14

80.19%





MAII K5

71.9 %



MAII K14


62.3%



## 4.B


SNA K8/18

72.2%




SNA K19

70%





MAII K8/18

89.6%



MAII K19


89%





## 4.C

SNA  $\beta$  tubulin


58.4%

MAII  $\beta$  tubulin


38 %







5. A




5.B







7. A- A/MEMPHIS/257/2019 (H3N2)





7. B- A/RG/WSN/33



7. C- A/TENNESSEE/1-560/2009 (H1N1)









Mock
  WSN
  pH1N1
  H3N2


8. S




8. T



8. U



8. V



8. W

